Skip to content

Cellectar Biosciences, Inc.: 10-Q filed 2018-08-10

What Cellectar Biosciences, Inc. reported in its quarterly report filed 2018-08-10 (fiscal Q2 2018): 26 published measures, 66 facts as tagged in accession 0001144204-18-043453.

This filing

Form
10-Q (quarterly report)
Filed
2018-08-10
Fiscal period
fiscal Q2 2018
Accession
0001144204-18-043453 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Cellectar Biosciences, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2018-06-306,996,821USD
At 2017-12-3112,871,464USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2018-06-302,289,855USD
At 2017-12-312,117,001USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2018-06-304,706,966USD
At 2017-12-3110,754,463USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2018-06-304,180,744USD
At 2017-12-3110,006,421USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2018-04-01 to 2018-06-30-2,920,691USD91
2018-01-01 to 2018-06-30-6,396,514USD181
2017-04-01 to 2017-06-30-3,121,528USD91
2017-01-01 to 2017-06-30-6,012,853USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-01-01 to 2018-06-30-5,729,636USD181
2017-01-01 to 2017-06-30-5,651,030USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2018-01-01 to 2018-06-301,425USD181
2017-01-01 to 2017-06-30320,510USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2018-01-01 to 2018-06-30-94,616USD181
2017-01-01 to 2017-06-302,839,994USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2018-01-01 to 2018-06-30-1,425USD181
2017-01-01 to 2017-06-30-320,510USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2018-06-30-90,745,830USD
At 2017-12-31-84,349,316USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2018-06-30211,970USD
At 2017-12-31244,713USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2018-04-01 to 2018-06-30175,579USD91
2018-01-01 to 2018-06-30349,017USD181
2017-04-01 to 2017-06-30231,086USD91
2017-01-01 to 2017-06-30396,760USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2018-04-01 to 2018-06-30-2,904,919USD91
2018-01-01 to 2018-06-30-6,358,446USD181
2017-04-01 to 2017-06-30-3,216,469USD91
2017-01-01 to 2017-06-30-6,028,706USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2018-06-305,016,303USD
At 2017-12-3110,939,417USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2018-06-302,289,287USD
At 2017-12-312,114,788USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2018-06-301,675,462USD
At 2017-12-311,675,462USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2018-04-01 to 2018-06-301,723,087USD91
2018-01-01 to 2018-06-303,802,955USD181
2017-04-01 to 2017-06-302,175,929USD91
2017-01-01 to 2017-06-304,032,810USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2018-06-301,774,992shares
At 2017-12-311,666,144shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2018-06-304,235,744USD
At 2017-12-3110,061,421USD
At 2017-06-308,368,073USD
At 2016-12-3111,499,619USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2018-06-3095,452,779USD
At 2017-12-3194,107,981USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2018-06-3093,086USD
At 2017-12-3111,872USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2018-06-30780,559USD
At 2017-12-31877,996USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2018-04-01 to 2018-06-301,181,832USD91
2018-01-01 to 2018-06-302,555,491USD181
2017-04-01 to 2017-06-301,040,540USD91
2017-01-01 to 2017-06-301,995,896USD181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2018-01-01 to 2018-06-3034,168USD181
2017-01-01 to 2017-06-30188,325USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2018-04-01 to 2018-06-30-15,772USD91
2018-01-01 to 2018-06-30-38,068USD181
2017-04-01 to 2017-06-3094,941USD91
2017-01-01 to 2017-06-3015,853USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2018-01-01 to 2018-06-300USD181
2017-01-01 to 2017-06-30364USD181

Inspect the source

Entity
Cellectar Biosciences, Inc. / CIK 0001279704
Captured
2026-09-20T07:48:31.991Z
SEC response SHA-256
44da00fed89c835867d9290b98319109f07ad849957763fd081353f99891a212

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001279704.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))